Stay informed with the latest litigation news. Explore now

Propylene Glycol-Containing Peptide Formulations Which Are Optimal For Production And For Use In Injection Devices - EP1687019B1

EP1687019

NOVO NORDISK
Application Number
EP04797453A
Filing Date
Nov 18, 2004
Status
Opposition Rejected
Jan 20, 2023
Grant Date
Nov 22, 2017
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Bibliography

The patent EP1687019B1 was granted to Novo Nordisk on Nov 22, 2017 following the initial filing on Nov 18, 2004 under the application number EP04797453A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

UEXKULL & STOLBERG PARTNERSCHAFT VON PATENT UND RECHTSANWALTEN MBBAug 22, 2018ADMISSIBLE
GENERICS UKAug 21, 2018ADMISSIBLE
TEVA PHARMACEUTICALSAug 21, 2018ADMISSIBLE
WITTKOPPAug 21, 2018ADMISSIBLE
FRESENIUS KABI DEUTSCHLANDAug 20, 2018ADMISSIBLE
SANDOZAug 20, 2018ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents